Literature DB >> 33850297

A Decade of Pharmacogenetic Studies in Jordan: A Systemic Review.

Alaa Yehya1, Zaid Altaany2.   

Abstract

The aim of this study was to perform a systematic overview of the pharmacogenetic studies conducted in Jordan. A structured search of Medline was conducted for articles over the last decade (January 2010-July 2020). Studies were classified by design, sample size, drug-gene combination, and the significance of the results. Thirty-two studies met the criteria for review. Most pharmacogenomic studies had a case-only design (n = 23). Only five studies included >500 participants. The total number of genetic variants in all studies was one hundred fifteen, which were found in forty genes, including dynamic (n = 27), and kinetic (n = 9) genes. The most commonly studied drugs were within the hematology and cardiology therapeutic areas and included statins, warfarin, aspirin, and clopidogrel. Most studies (n = 18) reported results with mixed p values [<0.05 and >0.05]. Pharmacogenomic research in Jordan is still in its infancy and is limited mainly to replication attempts. The need for standardization is imperative, especially in developing countries with scarce funding resources.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Year:  2021        PMID: 33850297     DOI: 10.1038/s41397-021-00236-6

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  51 in total

1.  Pharmacogenetics and pharmacogenomics.

Authors:  M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Case-control association studies in pharmacogenetics.

Authors:  S T Weiss; E K Silverman; L J Palmer
Journal:  Pharmacogenomics J       Date:  2001       Impact factor: 3.550

3.  Pharmacogenomics in drug development: societal and technical aspects.

Authors:  T Bartfai
Journal:  Pharmacogenomics J       Date:  2004       Impact factor: 3.550

Review 4.  The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies.

Authors:  Pablo Alonso-Coello; Affan Irfan; Ivan Solà; Ignasi Gich; Mario Delgado-Noguera; David Rigau; Sera Tort; Xavier Bonfill; Jako Burgers; Holger Schunemann
Journal:  Qual Saf Health Care       Date:  2010-12

Review 5.  Cohort studies: prospective versus retrospective.

Authors:  Anne M Euser; Carmine Zoccali; Kitty J Jager; Friedo W Dekker
Journal:  Nephron Clin Pract       Date:  2009-08-18

Review 6.  The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.

Authors:  Xiantao Zeng; Yonggang Zhang; Joey S W Kwong; Chao Zhang; Sheng Li; Feng Sun; Yuming Niu; Liang Du
Journal:  J Evid Based Med       Date:  2015-02

Review 7.  Pharmacogenetics goes genomic.

Authors:  David B Goldstein; Sarah K Tate; Sanjay M Sisodiya
Journal:  Nat Rev Genet       Date:  2003-12       Impact factor: 53.242

Review 8.  Cost-effectiveness analyses of genetic and genomic diagnostic tests.

Authors:  Katherine Payne; Sean P Gavan; Stuart J Wright; Alexander J Thompson
Journal:  Nat Rev Genet       Date:  2018-01-22       Impact factor: 53.242

Review 9.  The emerging era of pharmacogenomics: current successes, future potential, and challenges.

Authors:  J W Lee; F Aminkeng; A P Bhavsar; K Shaw; B C Carleton; M R Hayden; C J D Ross
Journal:  Clin Genet       Date:  2014-05-09       Impact factor: 4.438

Review 10.  Randomized controlled trials - a matter of design.

Authors:  Peter Markus Spieth; Anne Sophie Kubasch; Ana Isabel Penzlin; Ben Min-Woo Illigens; Kristian Barlinn; Timo Siepmann
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-10       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.